Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer …
Post
-
-
Vanda puts anxiety drug’s development on ice after Phase III fail
Vanda Pharmaceuticals has hit pause on a late-stage programme evaluating its small molecule drug, VQW-765, after it failed to demonstrate …
-
Spinogenix adds Phase IIb autism study to CLARITY basket trial
Spinogenix has broadened its ongoing Phase IIb/III CLARITY basket trial to include a Phase IIb study of codabakalner (SPG601) in …
-
Pilatus doses first patient in Phase I PLT012 trial for HCC
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing …
-
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a …
-
Pilatus doses first patient in Phase I PLT012 trial for HCC
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing …
-
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a …
-
MHRA homes in on personalised healthcare and tech in new 2030 strategy
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has devised a new strategy to better harness advancements in personalised …
-
Trials to watch: First cancer vaccine success could trigger a domino effect
Katalin Karikó and Drew Weissman’s Nobel Award-winning discovery that pushed mRNA therapies to the next level gained high praise during …
-
IgniteData, RealTime join forces to automate clinical trial data transfers
US-based clinical research software providers IgniteData and RealTime eClinical Solutions have announced a partnership to connect their systems and automate …
-
Dosing completed in Calluna Pharma’s Phase II AURORA trial
Calluna Pharma has completed patient dosing in its Phase II AURORA trial of CAL101 to treat idiopathic pulmonary fibrosis (IPF). The …
-
BioNTech misses PFS endpoints in Phase II/III cancer vaccine trial
One of BioNTech's prospective cancer vaccines has failed to show benefit in one of its dual primary endpoints in a …
-
Regeneron reports 84-week Phase III data for Pasatru in adult FOP
Regeneron Pharmaceuticals has reported 84-week findings from the Phase III OPTIMA trial assessing Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans …
-
Tortugas’ Phase IIb schizophrenia trial of obuprazine meets primary endpoint
Tortugas Neuroscience and its partner Hansoh Pharma have reported that their Phase IIb clinical trial of obuprazine (TRTL-107) for acute …
-
Women’s health landscape shifting, but systemic hurdles remain
It is no secret that research and development (R&D) efforts to improve care in women’s health have long been critically …
